 |
|
|
|
|
|
1.
Baltzer AWA, Ostapczuk MS, Stosch D, Granrath M. (2012)
The use of rhBMP-2 for the treatment of a delayed union following femoral neck
open-wedge osteotomy. Orthopaedic Reviews 4:e4
http://www.pagepress.org/journals/index.php/or/article/view/or.2012.e4
2.
The participants of the ISMO 2005 Meeting in Arosa, Switzerland came to the conclusion that the field of Molecular Orthopaedics is making steady progress towards the clinical application of molecular therapies in certain orthopaedic indications . All major fields of orthopaedics, including rheumatology, were addressed by the speakers, who came from different countries, and represented different scientific and medical backgrounds.
The scientific sessions were dominated by excellent keynote lectures from Prof. Chris Evans, Harvard Medical School, Boston and the excellent slides of Prof. Paul Robbins, University of Pittsburgh School of Medicine.
Both speakers presented new ideas and addressed new approaches to the molecular treatment of pressing clinical problems in orthopaedics and rheumatology. The ISMO board members decided to organize the ISMO as an open forum with an annual meeting. The main topic and sense of the ISMO is to focus on translational research, to get researchers, clinicians, and companies under one roof, and so enable fast interactions s to finally move this highly potential field of Molecular Orthopaedics into clinical reality.
3.
Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res. 2004 Sep-Oct;24(5A):2861-7 IL-23 does not show the immuno-therapeutic effectivity for adjuvant treatment of osteosarcomas like IL-12 and IL-18 do, when taking only IFN-gamma induction into consideration.
4.
Feasibility of percutaneous gene transfer to an atrophic nonunion in a rabbit. Clin Orthop. 2004 Aug(425):237-43 The described model reliably leads to an atrophic tibial nonunion in rabbits. Adenoviral percutaneous gene delivery into the nonunion site is feasible and leads to transgene expression locally for at least 1 month. This study provides investigators with a reliable and reproducible model of an atrophic nonunion.
5.
Regional gene therapy to enhance bone repair. Gene Ther. 2004 Feb;11(4):344-50. Review The purpose of this review is to highlight the advantages, disadvantages and clinical potential of various gene therapy strategies to enhance bone repair.
6.
Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum Preliminary results from prospective multicentric studies of approximately 1000 treated knee joints with osteoarthritis grade I ^III according to the Kellgren classification reveal that 70-75% of the patients report pain relief ranging from 50-100%. After 3.5 years 35-40% of the patients still report benefit from the treatment. No serious side effects were observed in more than 6000 injections. The intraarticular application of autologous, artificially conditioned serum appears to be a safe, and effective long-term alternative to standard conservative treatments of osteoarthritis.
